# Framewise Integrated Real-Time MRI Monitoring (FIRMM) software commercialization readiness for clinical care

> **NIH NIH SB1** · TURING MEDICAL TECHNOLOGIES INC · 2024 · $1,103,248

## Abstract

Project Abstract/Summary
 Motion related artifacts are a significant source of cost to the healthcare system. With over 12,000 MRI
scanners in the U.S. and estimates that $434,000 are lost per scanner each year, motion in MRIs is costing our
health care system approximately $4B yearly. Our FDA-cleared software solution Framewise Integrated Real-
Time MRI Monitoring (FIRMM) mitigates data lost due to motion. However, the majority of paying customers so
far are academic neuroimaging research centers; in order to ensure the commercial success of FIRMM, we
need to expand the customer base to clinical institutions. The goal of this CRP application is to fill gaps in
FIRMM clinical commercialization sales by partnering with Siemens and building functionality to streamline
clinical use of FIRMM and FIRMM-pix.
 Leading hospitals have expressed enthusiasm to use FIRMM for clinical care; however, two main
barriers to clinical adoption remain: a reduction in technician critical decision making and a seamless
integration into existing clinical workflows. Both of these barriers can be overcome via Siemens’ Access-I,
which provides an FDA approved licensing and authentication scheme to enable secure and direct operation of
Siemens systems from any 3rd party vendor device. Pairing the FIRMM tablet with Siemens' Access-I module
will allow for the FIRMM tablet to re-start a scan automatically when the quality is low via a direct interaction
with the clinical scanner, thus saving time, easing workflows, and standardizing decision making for
technicians. Integrating the FIRMM tablet with Siemens' Access-I will lead to a more seamless integration into
existing workflows; thus reducing the disruption to existing complex clinical workflows.
 In addition, integrating the FIRMM tablet with Siemens' Access-I module will facilitate the wide-spread
adoption of FIRMM(-pix) in the clinical market by obtaining widespread visibility via co-marketing with Siemens
Healthineers and their catalog. Importantly, this partnership with Siemens is planned only as an initial step to
establishing clinical commercialization sales. Although Siemens is the leading MRI manufacturer, GE and
Philips combine with Siemens to account for almost 90% of the MRI market. The proposed activities in this
CRP will form the basis of future work to establish similar partnerships with GE and Philips. Overall, this CRP
is perfectly positioned to put FIRMM and its subsequent products on a pathway to long-term success.

## Key facts

- **NIH application ID:** 11002089
- **Project number:** 5SB1MH133465-02
- **Recipient organization:** TURING MEDICAL TECHNOLOGIES INC
- **Principal Investigator:** Kevin King
- **Activity code:** SB1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,103,248
- **Award type:** 5
- **Project period:** 2023-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11002089

## Citation

> US National Institutes of Health, RePORTER application 11002089, Framewise Integrated Real-Time MRI Monitoring (FIRMM) software commercialization readiness for clinical care (5SB1MH133465-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/11002089. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*